Relief from the constant call of nature is the aim of a new drug, tested in rats, which can shrink an enlarged prostate and is likely to have few side effects.
By the age of 60 an estimated 70 per cent of men have prostate enlargement. Treatment involves surgery or drugs that block , a hormone that drives unwanted growth. Side effects can include loss of libido and erectile dysfunction.
The new drug, RC-3940-II, developed by Andrew Schally of the Miami Veterans Affairs Medical Center in Florida and colleagues works by blocking gastrin-releasing peptide – another potent growth factor.
In rats, a six-week treatment shrank prostates by 18 per cent. It also shrank human prostate cells by 21 per cent. Importantly, fewer side effects are likely as pathways are avoided.
Journal reference: PNAS, DOI: 10.1073/pnas.1222355110
